Therefore, these results suggest that oral administration of APX3330 may be a superior route of administration to IP injections to reduce lesion size, indicating that APE1/Ref-1 redox inhibitors such as APX3330 may be potential oral therapeutics for neovascular eye diseases. The gene discussed is APEX1; the disease is eye disorder.